| 中文名稱:TAS6417 | 英文名稱:TAS6417 |
| CAS:1661854-97-2 | 品牌: 阿拉丁 |
| 產(chǎn)地: 上海 | 保存條件: 避光,-20°C儲存,充氬 |
| 純度規(guī)格: Moligand?, ≥99% | 產(chǎn)品類別: 小分子和化合物庫 配體家族 |
| 分子式: C23H20N6O | 分子量: 396.44 |
| 運(yùn)輸條件: 超低溫運(yùn)輸 | 產(chǎn)品規(guī)格: 5mg、100mg、10mg |
| 貨號: T414199 | 是否進(jìn)口: 否 |
中文名:TAS6417
英文名:TAS6417
純度:Moligand?,≥99%
貨號:T414199
Cas號:1661854-97-2
存儲溫度:避光,-20°C儲存,充氬
運(yùn)輸條件:超低溫運(yùn)輸
產(chǎn)品介紹:
Information
TAS6417 (CLN-081, TPC-064) is a novelEGFRinhibitor that targets EGFR exon 20 insertion mutations while sparing wild-type (WT) EGFR. IC50 values ranges from 1.1 ± 0.1 to 8.0 ± 1.1 nmol/L.
Targets
EGFR(d746-750/T790M) (Cell-free assay); TXK (Cell-free assay); EGFR(d746-750) (Cell-free assay); EGFR L858R (Cell-free assay); EGFR T790M/L858R (Cell-free assay) 31954,1.1 nM; 1.1 nM; 1.4 nM; 1.9 nM; 2 nM
In vitro
Of the 255 kinases tested, TAS6417 inhibits 25 kinases other than EGFR with IC50 values less than 1,000 nmol/L, which was 100 times higher than its IC50 value against WT EGFR. It inhibits only six kinases containing TXK, BMX, HER4, TEC, BTK, and JAK3, with IC50 values less than 10 times that against WT EGFR. TAS6417 inhibits proliferation of Ba/F3 cells driven by various EGFR exon 20 insertion mutations, with IC50 values ranging from 5.05 ± 1.33 nmol/L to 150 ± 53 nmol/L. It also suppresses the growth of cells expressing exon 20 insertion mutations of the EGFR gene, with a GI50 value of 86.5 ± 28.5 nmol/L for LXF 2478L cells and 45.4 ± 2.6 nmol/L for NCI-H1975 EGFR D770_N771insSVD cells. TAS6417 has no effect on EGFR-independent proliferation in NCI-H23 or NCI-H460 cells.
In vivo
TAS6417 causes persistent tumor regression in vivo in EGFR exon 20 insertion-driven tumor models. The tumor regression occurrs quickly after TAS6417 treatment and persists during the treatment period. Pharmacokinetic analysis reveals that the plasma concentration of TAS6417, administered at 50 and 100 mg/kg to mice, decreases rapidly in the first 4 hours. In contrast, although the effective doses in the rat model exhibit lower maximum plasma concentration (Cmax) values than those in the mouse model, the plasma concentrations tend to be more persistent, lasting up to 8 hours. TAS6417 inhibits mutant EGFR in tumors but not WT EGFR in skin tissues. It prolongs survival of animals bearing lung cancer.
Cell Research(from reference)
Cell lines:LXF 2478L cells and NCI-H1975 EGFR D770_N771insSVD cells?
Concentrations:0-1 μM?
Incubation Time:6 and 24 hours?
查看阿拉丁官網(wǎng)此產(chǎn)品相關(guān)對應(yīng)頁面:https://www.aladdin-e.com/zh_cn/T414199.html



| 成立日期 | 2009-03-16 (18年) | 注冊資本 | 14130.676萬人民幣 |
| 員工人數(shù) | 500人以上 | 年營業(yè)額 | ¥ 1億以上 |
| 主營行業(yè) | 生物化工,化學(xué)試劑 | 經(jīng)營模式 | 工廠,試劑 |
| 產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
|---|---|---|---|---|
| ¥3000 |
VIP10年
|
湖北威德利化學(xué)試劑有限公司
|
2026-07-29 | |
| 詢價 |
VIP2年
|
陜西格列弗生物科技研究有限責(zé)任公司
|
2026-07-27 | |
| ¥828 |
VIP5年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2026-07-27 | |
| 詢價 |
VIP6年
|
安慶百諾醫(yī)藥科技有限公司
|
2026-07-24 | |
| 詢價 |
VIP6年
|
武漢鼎信通藥業(yè)有限公司
|
2026-07-24 | |
| ¥1350 |
VIP5年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2026-07-21 | |
| ¥450 |
VIP6年
|
濟(jì)南川貝生物科技有限公司
|
2026-07-09 | |
| 詢價 |
VIP15年
|
上海厚博生物科技有限公司
|
2026-06-01 | |
| 詢價 |
VIP14年
|
上海陶術(shù)生物科技有限公司
|
2026-05-08 | |
| 詢價 |
泰州市高港區(qū)進(jìn)燕生物技術(shù)有限公司
|
2026-04-16 |